Classes
DEA Class; Rx
Common Brand Names; Atacand HCT
- ARB/HCTZ Combos
Description
Angiotensin II antagonist and thiazide diuretic used together for management of HTN; additive efficacy; less potassium loss compared to diuretic monotherapy.
Indications
Indicated for the treatment of hypertension in patients who do not respond to monotherapy.
Contraindications
Hypersensitivity to candesartan, hydrochlorothiazide, or sulfonamides
Pregnancy (2nd and 3rd trimesters): Significant risk of fetal/neonatal morbidity and mortality
Gout
Refractory hypercalcemia
Refractory hypokalemia
Severe hepatic impairment and/or cholestasis
Do not coadminister with aliskiren in patients with diabetes mellitus
As initial therapy
Adverse Effects
Adverse reactions with combination products and individual agents
Headache (3%)
Dizziness (3%)
Upper respiratory tract infection (4%)
Back pain (3%)
Flu-like syndrome (2%)
Candesartan
- Peripheral edema
- Dizziness
- Fatigue
- Abdominal pain
- Diarrhea
- Nausea
- Arthralgia
- Back pain
- Chest pain
- Albuminuria
- Bronchitis
- Coughing
- Pharyngitis
- Rhinitis
- URI
Hydrochlorothiazide
- Anorexia
- Epigastric distress
- Hypotension
- Orthostatic hypotension
- Photosensitivity
- Anaphylaxis
- Anemia
- Confusion
- Erythema multiforme
- Stevens-Johnson syndrome
- Exfoliative dermatitis including toxic epidermal necrolysis
- Dizziness
- Headache
- Hyperuricemia
- Hypokalemia and/or hypomagnesemia
Warnings
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without history of allergy or bronchial asthma, but are more likely in patients with such a history
Acute transient myopia and acute angle-closure glaucoma has been reported, particularly with history of sulfonamide or penicillin allergy (hydrochlorothiazide is a sulfonamide)
Photosensitivity may occur; instruct patients taking hydrochlorothiazide to protect skin from sun and undergo regular skin cancer screening
Monitor serum electrolytes periodically; drugs that inhibit the renin-angiotensin system can cause hyperkalemia; hydrochlorothiazide can cause hypokalemia and hyponatremia; hypomagnesema can result in hypokalemia which appears difficult to treat despite potassium repletion
Thiazides decrease urinary calcium excretion and may cause mild elevation of serum calcium; avoid therapy in patients with hypercalcemia
Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for renal function changes (including acute renal failure) compared to monotherapy
Caution in aortic mitral stenosis, hepatic impairment, hypercholesterolemia, hypercalcemia, parathyroid disease, pre-existing renal insufficiency, systemic lupus erythematosus, bilateral renal artery stenosis or anuria
Hydrochlorothiazide may alter glucose tolerance and raise serum levels of cholesterol and triglycerides
Thiazides may decrease urinary calcium excretion
Pregnancy and Lactation
Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)
Lactation: enters breast milk/contraindicated
Maximum Dosage
32 mg/day PO candesartan and 25 mg/day PO hydrochlorothiazide.
32 mg/day PO candesartan and 25 mg/day PO hydrochlorothiazide.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
candesartan/hydrochlorothiazide
tablet
- 16mg/12.5mg
- 32mg/12.5mg
- 32mg/25mg